This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The Cooper Companies Inc (COO), based in Pleasanton, CA, is a specialty medical device company operating on a global basis. Cooper has two business segments- CooperVision (CVI) and CooperSurgical (CSI). CooperVision manufactures and sells a wide range of contact lenses. CooperVision develops manufactures and markets a broad range of single-use, two-week and monthly contact lenses, featuring advanced materials and optics. The company’s products are primarily designed for solving vision challenges like astigmatism, presbyopia and ocular dryness. CooperSurgical sells a variety of medical devices and surgical instruments that are primarily utilized by gynecologists and obstetricians. This strategic business unit has pursued a strategy of consolidation by acquiring critical treatment niches in a fragmented market.
Cooper Companies (COO) Earnings Miss & Revenues Beat in Q3
by Zacks Equity Research
Cooper (COO) gains from solid CSI revenues in Q3; international revenues surge.
Cooper Cos. (COO) Q3 Earn Earnings ings Lag Estimates
by Zacks Equity Research
Cooper Cos. (COO) delivered earnings and revenue surprises of -2.60% and 1.00%, respectively, for the quarter ended July 2018. Do the numbers hold clues to what lies ahead for the stock?
Cooper Cos. (COO) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Cooper Cos. (COO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Cooper Companies' (COO) Q3 Earnings?
by Zacks Equity Research
Cooper Companies (COO) is likely to gain from strong segmental show in Q3; a competitive industry raises concern.
Will Medtronic (MDT) Q1 Earnings Show Overall Progress?
by Zacks Equity Research
In Q1, Medtronic (MDT) is expected to have sustained a steady market share across the core pacing, ICD and CRT product lines.
Intuitive Surgical Gains From Solid Q2 and Strong AI Exposure
by Zacks Equity Research
Intuitive Surgical's (ISRG) impressive second-quarter 2018, strength in robotics and AI trends buoy optimism.
CVS Health's PBM Selling Season Strong, Aetna Deal on Track
by Zacks Equity Research
A solid 2019 PBM selling season is a significant positive for CVS Health's (CVS) growth. The company completes more than 70% of its client renewals, almost in line with the prior-year level.
Amedisys (AMED) Grows on Robust Home Health, Personal Care
by Zacks Equity Research
Amedisys' (AMED) solid performance in Personal Care division is impressive. Plus, a favorable demographic trend and calculating buyouts bode well for the company.
Can Cooper Cos. (COO) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Cooper Cos. (COO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Integra LifeSciences Codman Arm Strong, Competition Rife
by Zacks Equity Research
Integra LifeSciences' (IART) progress within its channel expansion strategy and Codman integration buoys investors' optimism on the stock.
Inogen's Solid Europe Business Shapes Q2, Prospects Bright
by Zacks Equity Research
Inogen's (INGN) Europe performance solid in Q2; guidance for 2018 encourages.
Surmodics' (SRDX) IVD Unit Boosts Growth, R&D Focus Solid
by Zacks Equity Research
Surmodics' (SRDX) strong focus on R&D to provide it a competitive edge in the MedTech space.
Boston Scientific to Expand Within PI Via VENITI Buyout
by Zacks Equity Research
Presence of venous obstructive disease visibly grows across the globe, indicating huge prospects for Boston Scientific (BSX) in the treatment market.
Here's Why You Should Dump DENTSPLY (XRAY) Stock Right Now
by Zacks Equity Research
DENTSPLY (XRAY) incurs goodwill and intangible impairment charge. A lowered guidance is a concern.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Ecolab (ECL) is likely to gain from a robust product portfolio, new product launches and expanding customer base.
Varian Acquires humediQ, Boosts Motion Management Portfolio
by Zacks Equity Research
Varian (VAR) incorporates humediQ's coveted IDENTIFY technology in its comprehensive suite of oncology solutions.
COO or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COO vs. MMSI: Which Stock Is the Better Value Option?
What's in Store for Pacific Biosciences' (PACB) Q2 Earnings?
by Zacks Equity Research
Pacific Biosciences' (PACB) flagship Sequel System is likely to drive Q2 results; competition is a headwind.
Can Kidney Care Business Drive DaVita's (DVA) Q2 Earnings?
by Zacks Equity Research
DaVita's (DVA) flagship Kidney Care business likely to drive Q2 results; solid international presence encourages.
Why Cardinal Health (CAH) Could Be Positioned for a Slump
by Zacks Equity Research
Cardinal Health (CAH) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
GNC Holdings' Global Prospects Solid, Competition Stiff
by Zacks Equity Research
GNC Holdings (GNC) progresses with deals to boost international presence.
What's in Store for DENTSPLY (XRAY) This Earnings Season?
by Zacks Equity Research
DENTSPLY's (XRAY) CAD/CAM unit is likely to drive the top line in Q1. Product innovations and strong R&D prospects are also likely to drive growth.
What's in Store for AmerisourceBergen (ABC) in Q2 Earnings?
by Zacks Equity Research
Despite solid prospects in the Pharmaceutical Distribution segment, a temporary slowdown in the PharMEDium unit is likely to mar AmerisourceBergen's (ABC) Q2 earnings.
Can PBM Unit Boost Express Scripts' (ESRX) Q1 Earnings?
by Zacks Equity Research
Impressive performance by the PBM unit is likely to drive Express Scripts' (ESRX) Q1 earnings.
Why Is Cooper Companies (COO) Down 10.1% Since its Last Earnings Report?
by Zacks Equity Research
Cooper Companies (COO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.